Douglas J. Schwartzentruber

Douglas J. Schwartzentruber publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Douglas J. Schwartzentruber sits on this spectrum.

Douglas J. Schwartzentruber D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Douglas J. Schwartzentruber sits on this spectrum.

Best Publications

• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

  Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang

  3729
  Citations

• A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

  James C. Yang;Leah Haworth;Richard M. Sherry;Patrick Hwu

  3529
  Citations

• Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

  S A Rosenberg;B S Packard;P M Aebersold;D Solomon

  3335
  Citations

• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  Steven A. Rosenberg;James C. Yang;Douglas J. Schwartzentruber;Patrick Hwu

  2270
  Citations

• Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

  Giao Q. Phan;James C. Yang;Richard M. Sherry;Patrick Hwu

  1911
  Citations

• Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2

  Steven A. Rosenberg;John R. Yannelli;James C. Yang;Suzanne L. Topalian

  1313
  Citations

• gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

  Douglas J. Schwartzentruber;David H. Lawson;Jon M. Richards;Robert M. Conry

  1097
  Citations

• Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer

  James C. Yang;Richard M. Sherry;Seth M. Steinberg;Suzanne L. Topalian

  1001
  Citations

• Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced Cancer

  Steven A. Rosenberg;Michael T. Lotze;James C. Yang;Suzanne L. Topalian

  817
  Citations

• Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma

  Steven A. Rosenberg;Richard M. Sherry;Kathleen E. Morton;William J. Scharfman;William J. Scharfman

  559
  Citations

• Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma

  Mark E. Dudley;John Wunderlich;Michael I. Nishimura;David Yu

  540
  Citations

• A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.

  Mark E. Dudley;John R. Wunderlich;James C. Yang;Patrick Hwu

  524
  Citations

• Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1.

  Sharilyn K. Stanley;Mario A. Ostrowski;Jesse S. Justement;Kira Gantt

  430
  Citations

• Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b

  Steven A. Rosenberg;James C. Yang;Douglas J. Schwartzentruber;Patrick Hwu

  419
  Citations

• Immunizing Patients With Metastatic Melanoma Using Recombinant Adenoviruses Encoding MART-1 or gp100 Melanoma Antigens

  Steven A. Rosenberg;Yifan Zhai;James C. Yang;Douglas J. Schwartzentruber

  387
  Citations

• Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV.

  Joseph A. Kovacs;Richard A. Lempicki;Igor A. Sidorov;Joseph W. Adelsberger

  275
  Citations

• A Breast and Melanoma-Shared Tumor Antigen: T Cell Responses to Antigenic Peptides Translated from Different Open Reading Frames

  Rong Fu Wang;Samuel L. Johnston;Gang Zeng;Suzanne L. Topalian

  267
  Citations

• High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

  Janice P Dutcher;Douglas J Schwartzentruber;Howard L Kaufman;Sanjiv S Agarwala

  227
  Citations

• Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.

  J C Yang;S L Topalian;D Parkinson;D J Schwartzentruber

  223
  Citations

• In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.

  Douglas J. Schwartzentruber;Sophia S. Hom;Roya Dadmarz;Donald E. White

  222
  Citations